| Item Type | Name |
|
Concept
|
Heart Failure
|
|
Concept
|
Heart Failure, Systolic
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
|
|
Academic Article
|
Heart failure as a cause for hospitalization in chronic dialysis patients.
|
|
Academic Article
|
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality.
|
|
Academic Article
|
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.
|
|
Academic Article
|
Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
|
|
Academic Article
|
Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
|
|
Academic Article
|
A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure.
|
|
Academic Article
|
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.
|
|
Academic Article
|
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study.
|
|
Academic Article
|
Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study.
|
|
Academic Article
|
A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure.
|
|
Academic Article
|
Isolated diastolic hypotension and incident heart failure in older adults.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
|
|
Academic Article
|
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies.
|
|
Academic Article
|
Renal adaptation to the failing heart. Understanding the cascade of responses.
|
|
Academic Article
|
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.
|
|
Academic Article
|
Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'.
|
|
Academic Article
|
Renal hemodynamic changes in heart failure.
|
|
Academic Article
|
Assessing kidneys that may be fragile.
|
|
Academic Article
|
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
|
|
Academic Article
|
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
The past, present and future of renin-angiotensin aldosterone system inhibition.
|
|
Academic Article
|
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure.
|
|
Academic Article
|
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
|
|
Academic Article
|
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
|
|
Academic Article
|
Advances in treatment of hyperkalemia in chronic kidney disease.
|
|
Academic Article
|
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
|
|
Academic Article
|
From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
|
|
Academic Article
|
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
|
|
Academic Article
|
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
|
|
Academic Article
|
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.
|
|
Academic Article
|
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
|
|
Academic Article
|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
|
|
Academic Article
|
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).
|
|
Academic Article
|
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
|
|
Academic Article
|
Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.
|
|
Academic Article
|
Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage.
|
|
Academic Article
|
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
|
|
Academic Article
|
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
|
|
Academic Article
|
Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure: Should We Be Surprised?
|
|
Academic Article
|
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review.
|
|
Academic Article
|
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
|
|
Academic Article
|
Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.
|
|
Academic Article
|
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
|
|
Academic Article
|
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
|
|
Academic Article
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents.
|
|
Academic Article
|
Kidney function assessment and endpoint ascertainment in clinical trials.
|
|
Academic Article
|
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
|
|
Academic Article
|
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
|
|
Academic Article
|
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review.
|
|
Academic Article
|
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial.
|
|
Academic Article
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
|
Academic Article
|
The changing trajectory of diabetic kidney disease.
|
|
Academic Article
|
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
|
|
Academic Article
|
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
|
|
Academic Article
|
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
|
|
Academic Article
|
Fluid retention and heart failure in the PRECISION trial - Authors' reply.
|
|
Academic Article
|
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
|
|
Academic Article
|
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
|
|
Academic Article
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
|
Academic Article
|
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus.
|
|
Academic Article
|
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.
|
|
Academic Article
|
Pathophysiological Sex Differences in Heart Failure Progression After Acute Coronary Syndrome: Insights From the EXAMINE Trial.
|
|
Academic Article
|
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
|
|
Academic Article
|
The evolution of "pillars of therapy" to reduce heart failure risk and slow diabetic kidney disease progression.
|